Blood Gas and Electrolyte Analyzer Provides Results in 50 Seconds
|
By LabMedica International staff writers Posted on 09 Sep 2008 |
|
A new blood gas and electrolyte (BGE) analyzer provides high quality measurements in just 50 seconds including blood gases (pH, PCO2, PO2), electrolytes (Na+, K+, Ca++, Cl-), and hematocrit (Hct). From the measurements a number of parameters are additionally calculated, for instance, base excess (BE).
Roche Diagnostics (Basel, Switzerland) announced the launch of the cobas b 121 blood gas analyzer in the EMEA region (Europe, Middle East, Africa), Asian, and Latin American markets. The cobas b 121 system meets expectations for a low cost, effective instrument for the rapid determination of blood gases and electrolytes.
The system supports clinical laboratories in facing the challenge of increasing cost pressure on healthcare. High levels of automation and low levels of maintenance mean very little operator intervention. This combined with its economy mode, maintenance-free, long-life sensors, and reusable waste bottles help to save costs.
The already existing cobas b 121 platform was simplified and reduced to the analytes needed for the rapid determination of blood gas and electrolytes status as well as acid base disorders. Although the complexity has been reduced on the system, it has kept the touch screen interface and high levels of on-board data management and connectivity. Customers currently using separate analyzers for blood gas and electrolyte measurements can now consolidate blood gases and electrolytes on one analyzer for greater efficiency.
The instrument is one of the fastest BGE systems for medium to high throughput (30 samples per hour) situations, and the maintenance-free sensors and high volume, reusable reagent bottles make it easy to operate and reliable. Calibrations are run automatically with a liquid calibration system, making it entirely gas-free.
Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system.
Related Links:
Roche Diagnostics
Roche Diagnostics (Basel, Switzerland) announced the launch of the cobas b 121 blood gas analyzer in the EMEA region (Europe, Middle East, Africa), Asian, and Latin American markets. The cobas b 121 system meets expectations for a low cost, effective instrument for the rapid determination of blood gases and electrolytes.
The system supports clinical laboratories in facing the challenge of increasing cost pressure on healthcare. High levels of automation and low levels of maintenance mean very little operator intervention. This combined with its economy mode, maintenance-free, long-life sensors, and reusable waste bottles help to save costs.
The already existing cobas b 121 platform was simplified and reduced to the analytes needed for the rapid determination of blood gas and electrolytes status as well as acid base disorders. Although the complexity has been reduced on the system, it has kept the touch screen interface and high levels of on-board data management and connectivity. Customers currently using separate analyzers for blood gas and electrolyte measurements can now consolidate blood gases and electrolytes on one analyzer for greater efficiency.
The instrument is one of the fastest BGE systems for medium to high throughput (30 samples per hour) situations, and the maintenance-free sensors and high volume, reusable reagent bottles make it easy to operate and reliable. Calibrations are run automatically with a liquid calibration system, making it entirely gas-free.
Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system.
Related Links:
Roche Diagnostics
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
TRAb Immunoassay
Chorus TRAb
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
Latest Clinical Chem. News
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
Channels
Molecular Diagnostics
view channel
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
